Детемір — унікальний аналог інсуліну продовженої дії

В. О. Малижев; О. А. Сакало

doi:10.24026/1818-1384.1(22).2008.118328

Автор(и)

В. О. Малижев Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ, Україна
О. А. Сакало Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ, Україна

DOI:

https://doi.org/10.24026/1818-1384.1(22).2008.118328

Ключові слова:

insulin analogues, pharmacokinetic and pharmacodynamic peculiarities, detemir

Анотація

In the present review the analysis of published data about pharmacokinetic and pharmacodynamic peculiarities of insulin analogue detemir is presented in comparison with other insulin medications of long-term action-insulin NPH and glargin. This insulin analogue of basal type because of its structure have a particular mechanism of prolonged action due to detemir ability to combine with interstitial fluid and plasma albumin molecules. In spite of this in contrast of other analogues insulin detemir is water soluble with neutral pH and do not leave a sediment in tissues after injections. In treatment of diabetes mellitus type 1 and 2 patients detemir has a similar action on glycemia control as insulin NPH and glargin. However, with the detemir use the lesser variability of glucose levels is present during whole day. In the same time insulin detemir have a unique ability to penetrate in the liver and its action on this organ is more intensive than at the periphery. At last insulin detemir in contrast of other insulins can selectively penetrate in to the brain tissue restoring hypothalamus and brain cortex activity, increasing functioning of energetic metabolism control mechanism and mental work. These peculiarities of detemir envisage a new approach of insulin therapy which is not related only to glicemia control.

Біографії авторів

В. О. Малижев, Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ

V. Malyzhev

О. А. Сакало, Український науково-практичний центр ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України, Київ

E. Sakalo

Посилання

Kolendorf K., Bojsen J., Deckert T. Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients // Horm. Metab. Res. — 1983. — V.15. — P. 274-278.

Jehle P.M., Micheler C. et al. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens // Lancet. — 1999. — V.354. — P. 307-335.

Bolli G.B., Perriello G. et al. Nocturnal blood glucose controle in type 1 diabetes mellitus// Diabetes Care. — 1993. — V.16. — P. 71-89.

Heinemann L. Variability of insulin absorption and insulin action // Diabetes Technol. Ther. — 2002. — V.4. — P. 673-682.

Bolli G.B., Owens D.R. Insulin glargine // Lancet. — 2000. — V.356. — P. 443-445.

Heise T., Nosek L. et al. Lower within—subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes // Diabetes. — 2004. — V.53. — P. 1614-1620.

Lindholm A. New insulins in the treatment of diabetes mellitus // Best. Pract. Clin. Gastroenterol. — 2002. — V.16. — P. 475-492.

Markussen J., Havelund S.. et al. Soluble fatty acid insulins bind to albumin and show protracted action in pigs // Diabetologia. — 1996. — V.39. — P. 281-288.

Dea M.K., Hamilton-Wessler M. et al. Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake // Diabetes. — 2002. — V.51. — P. 762-769.

Kurtzhals P., Schaffer L. et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use // Diabetes. — 2000. — V.49. — P. 999-1005.

Hansen B.F., Danielsen G.M. et al. Sustained signaling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency // Biochem. J. — 1996. — V.31. — P. 271-279.

Pieber T.R., Plank J. et al. Duration of action, pharmacodynamic profile and between - subject variability of insulin determine in subjects with type 1 diabetes // Diabetologia.— 2002. — V. 45.— Suppl. 2. — A254.

Brunner G.A., Sendhofer G. et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analoge NN304 in comparison to NPH insulin in humans // Exp. Clin. Endocrinol. Diabetes. — 2000. — V.108. — P.100-105.

Jacobsen L.V., Popescu G., Plum A. Pharmacokinetics of Levemir in subjects with renal or hepatic impairment // Diabetes. — 2002. — V.51. — Suppl. 2.— A102.

Kurtzhals P., Colding-Jorgensen M. Albumin binding of insulin detemir reduces the risk for hypoglycaemic events // Diabetes. — 2004. — V.53. — Suppl. 2. — A471.

Havelund S., Ribel U., Plum A. et al. The mechanism of protraction of insulin detemir, a long acting, acylated analoque of human insulin // Diabetes. — 2004. — V.53. — Suppl.1. — А462.

Strange P., McGill J., Mazzeo M. Reduced pharmacokinetic (PC) variability of a novel, long-acting insulin analog // Diabetes. — 1999. — V.48. — Suppl.1. — A103.

Kruszynska Y.T., Home P.D. et al. Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats // Diabetologia. — 1985. — V.28. — P. 167-171.

Jansen J.A., Lamberts S.W. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy // Clin. Endocrinol. — 2000. — V.52. — P.1-9.

Hordern S.V.M., Wright J.F. et al. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp // Diabetologia. — 2005. — V.48. — P. 420-426.

Ross M., Kaye G.I., Pawlina W. Histology a text and atlas. 4th ed. — Philadelphia, PA: Lippincott Williams and Wilkins, 2003. — P. 540-541.

Andreani D. Lights and shadows of insulin treatment seen by senior diabetologist // Exp. Clin. Endocrinol. Diabetes. — 1999. — V.107. — Suppl.2. — S.1—S.5.

Russell-Jones D., Simpson R. et al. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen // Clin. Ther. — 2004. — V.26. — P. 724-736.

De Leeuw I., Vague P. et al. Lower risk of nocturnal hypoglycaemia and favourable weight development in type 1 subjects after 12 months of treatment with insulin detemir vs NPH insulin // Diabetologia. — 2002. — V.45. — Suppl.2. — A799.

Vague P., Selam J-L. et al. Insulin detemir is associated with more predictable glycaemic control and lower risk of hypoglycaemia compared to NPH patients with type 1 diabetes on a basal bolus regimen with pre-meal insulin aspart // Diabetes Care. — 2003. — V.26. — P. 590-596.

Hermansen K., Fontaine P. et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes // Diabetologia. — 2004. — V.47. — P. 622-629.

Pieber T.R., Treichel H.-C. et al. Insulin detemir plus insulin aspart is assiciated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes // Diabetologia. — 2005. — Suppl.1. — A92.

The Diabetes Control and Complications Trial Research Group. The absence of a glycaemic threshold for the development of long-term complications // Diabetes. — 1996. — V.45. — P. 1289-1298.

Cryer P.E. Hypoglycaemia: The limiting factor in glycaemic management of type 1 and type 2 diabetes // Diabetologia. — 2002. — V.45. — P. 937-948.

Russell-Jones D., Kim H. et al. Insulin detemir reduces the risk of hypoglycaemia at all levels of HbA compared to to NPH insulin in the context of basal-bolus therapy for type 1 diabetes // Diabetologia. — 2005. — V.48. — Suppl.1. — A92.

Pieber T. Сomparison of pharmacodynamic and pharmacokinetic dose-response profiles between insulin detemir and NPH insulin in subjects with type 2 diabetes // Diabetes. — 2004. — V.53. — Supp.2. — A142.

Haak T., Tiengo A. et al. Lower within—subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes // Diabetes Obes. Metab. — 2005. — V.7. — P. 56-64.

Raslova K., Bogoev M. et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes // Diab. Res. Clin. Pract. — 2004. — V.662. — P. 193-201.

Rosenstock J., Davies M. et al. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes // Diabetologia. — 2008. — V.51. — P. 408-416.

Wallum B.J., Porte D. et al. Cerebrospinal fluid insulin levels increase during intravenous insulin infusion in man // J. Clin. Endocrinol. Metab. — 1987. — V.64. — P.190—194.

Lazar M. A. The humoral side of insulin resistance // Nat. Med. — 2006. — V.12. — P. 43-44.

Kern W., Benedict C. et al. Low cerebrospinal fluid insulin levels in obese humans // Diabetologia. — 2006. — V.49. — P. 2790-2792.

Schwartz M. W., Figlewicz D. P. et al. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats // Peptides. — 1990. — V.11. — P. 467-472.

Tschritter O., Porubska K. et al. Neuronal activation of the human cerebral cortex byadministration of insulin detemir compared to human insulin // Diabetologia. — 2005. — Suppl. 1. — A256.

Schick R.R., Schusdziarra V. et al. Neuropeptide Y and food intake in fasted rats: effect of naloxone and site of action // Brain Res. — 1991. — V.552. — P. 232-239.

BruningJ.C., Gautam D. et all. Role of brain insulin receptor in control of body weight and reproduction // Science. — 2000. — V.289. — P. 2122-2125.

DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial // Diabetes Care. — 1988. — V.11. — P. 567-573.

Hennige A. M., Sartorius T. et al. Tissue selectivity of insulin detemir action in vivo // Diabetologia. — 2006. — V.49. — P. 1274-1289.

Shen D.D., Artru A.A., Adkison K.K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics // Adv. Drug Deliv. Rev. — 2004. — V.56. — P. 1825-1857.

Gold S. M., Dziobek I. et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes // Diabetologia. — 2007. — V.50. — P. 711-719.

Wessels A. M., Rombouts S. A. R. B. et al. Cognitive perfomance in type 1 diabetes patients is associated with cerebral white matter volume // Diabetologia. — 2007. — V.50. — P. 1763-1769.

Henneberg N., Hoyer S. Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT) // Arch. Gerontol. Geriatr. — 1995. — V.21. — P. 63-74.

Schubert M., Brazil D. P. et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation // J. Neurosci. — 2003. — V.23. — P. 7084-7092.